Latest News & Features
Refine Search
Americas
Administration targets university’s federally funded research | Commerce Secretary warns of patent seizure under Bayh-Dole Act | Harvard given deadline to provide list of federally funded patents | Uncertainty continues across universities amid broader research cuts. 11 August 2025
Careers
The trio bring experience in patent, trade secret, and commercial disputes across high tech, biotech, and life sciences, with two returning to Weil after more than a decade. 11 August 2025
Americas
Payout and licensing deal grants US rights to COVID-19 and flu products | Agreement paves way for BioNTech’s $1.25 billion acquisition of CureVac. 8 August 2025
Europe
Captisol dispute intensifies as Italian court sides with Bexson | CyDex claims of trade secret misuse dismissed in early-stage ruling | Case relates to ongoing US dispute. 7 August 2025
Big Pharma
With AI accelerating drug development, pharma companies must rethink how they protect models, data, and innovation, say Camille Terfve and Sean Jauss of Mewburn Ellis. 6 August 2025
Careers
A litigator, who led the Unified Patent Court group at his previous firm, brings experience spanning the physics, software, and medical device sectors. 6 August 2025
Europe
A much-anticipated referral could upend the EPO’s controversial description amendment rule—and reshape European patent practice, as the Enlarged Board of Appeal prepares to weigh in on G 1/25. 5 August 2025
Europe
UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent. 4 August 2025
Unified Patent Court
Powell Gilbert experts share insights on how the Unified Patent Court is taking shape after two years in operation, in this session from LSPN. 4 August 2025
Europe
German Federal Patent Court invalidates key patent for Xarelto | Bayer faces intensifying generic competition across Europe | Legal team highlights Germany’s crucial role in patent litigation and the importance of stopping early generic entry to protect market exclusivity. 1 August 2025